Method helps identify preperimetric glaucoma

Article

The Random Forests machine learning method is a useful tool to help ophthalmologists distinguish between the visual fields (VFs) of individuals with healthy eyes and those with preperimetric open-angle glaucoma (OAG) in which glaucoma will manifest, according to research from Japan.

The Random Forests machine learning method is a useful tool to help ophthalmologists distinguish between the visual fields (VFs) of individuals with healthy eyes and those with preperimetric open-angle glaucoma (OAG) in which glaucoma will manifest, according to research from Japan published in Investigative Ophthalmology & Visual Science.

The investigators classified all VFs before an initial diagnosis of manifest glaucoma as preperimetric glaucoma VFs. They used the 30-2 threshold test programme of an automated perimeter (Humphrey Field Analyzer, Carl Zeiss Meditec) to obtain a series of 171 VFs in 53 eyes of 51 individuals with OAG or suspected OAG and from 108 healthy eyes of 87 individuals. They used the Random Forests method to calculate the area under the receiver operating characteristic curve (AROC) in distinguishing between the VFs of those with preperimetric glaucoma and those with healthy eyes; they used 52 total deviation (TD) values, mean deviation (MD) and pattern standard deviation (PSD) as predictors.

The researchers found a significant difference in MD and PSD between VFs of those with healthy eyes and the VFs of those with eyes with preperimetric glaucoma. They also observed a significant difference in the TD values between healthy VFs and preperimetric VFs at 25 out of 52 test points. The AROC obtained using the Random Forests method was 79%.

To read the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.